ABSTRACT. Objectives. To describe our experience with acute disseminated encephalomyelitis (ADEM), focusing on (1) the relationship between clinical course and MRI findings and (2) the response to plasmapheresis in a subgroup of patients.
A cute disseminated encephalomyelitis (ADEM) is usually a monophasic inflammatory demyelinating disease process that affects the brain and spinal cord and typically occurs after a febrile (often presumed to be viral) prodrome or vaccination. The typical presentation is that of multifocal neurologic disturbance accompanied by change in mental status. [1] [2] [3] MRI is regarded as the diagnostic imaging modality of choice and typically demonstrates involvement of deep cerebral hemispheric and subcortical white matter 4 as well as lesions in the basal ganglia, graywhite junction, diencephalon, brainstem, cerebellum, and spinal cord. 5, 6 To our knowledge, delayed MRI findings with a lag between clinical symptoms and MRI changes have not been previously described in children.
Treatment with corticosteroids is considered to hasten recovery 7, 8 and is accepted as the mainstay of therapy. Intravenous immunoglobulin (IVIG) has been reserved for patients who do not respond to corticosteroids. 9, 10 Use of plasmapheresis to treat this condition is limited to case reports. 11 The objective of this study was to describe our experience with ADEM, focusing on (1) the relationship between clinical course and MRI findings and (2) the response to plasmapheresis in a subgroup of patients.
METHODS
We retrospectively reviewed the medical records of children who received a diagnosis of ADEM during the period 1998 -2003 at St Christopher's Hospital for Children, a tertiary care medical center in North Philadelphia. Cases were identified by reviewing the ADEM code applied to the discharge diagnosis and the database of admissions in the Section of Neurology. Chart review was performed according to the hospital's Institutional Review Board policy.
Patients were included when they had an acute onset of neurologic disturbance and MRI changes involving white matter in a distribution previously described with ADEM. [1] [2] [3] Patients were excluded when they had infectious meningitis or encephalitis identified by isolation of a bacterial or a viral pathogen. Three patients who had a clinical picture consistent with transverse myelitis had additional lesions in brainstem and thalami indicative of disseminated demyelinating disease. Whenever available, the results of serologic testing, cerebrospinal fluid (CSF) examination, electroencephalogram, and other ancillary testing were included. All patients had serologic testing for Mycoplasma, EpsteinBarr virus, herpes simplex virus, and Lyme disease as well as nasopharyngeal and rectal viral cultures. Patients in whom a viral or bacterial pathogen was identified on culture, serology, or polymerase chain reaction studies were excluded from this series. All patients had a work-up to exclude vasculitis, which typically included a sedimentation rate, antinuclear antibodies, and rheumatoid factor. Magnetic resonance angiography was performed in selected patients in whom it was believed to be indicated. A 1.5-T Siemens machine was used for the brain MRI studies. T1, T2, fluid attenuated inversion recovery (FLAIR), and diffusion-weighted images were obtained. A pediatric neuroradiologist (E.N.F.) reviewed MRI scans and made special note of imaging changes with respect to the patient's clinical symptoms temporally.
Methylprednisolone was administered intravenously at a dose of 20 to 30 mg/kg per day for 5 days followed by a 2-week tapering dose. Immunoglobulin was administered intravenously at a dose of 0.4 g/kg per day for 5 days. Plasmapheresis when performed was instituted using single-volume exchange by continuous flow centrifugation. Volume that was removed was replaced by 5% albumin. Five plasma exchanges were administered on an every-other-day schedule. All patients who underwent plasmapheresis had previous placement of a central venous catheter and were monitored in the ICU. The functional degree of neurologic disability for all ambulatory patients was assessed using the Kurtzke functional systems 12 and Expanded Disability Status Scale (EDSS), as has been done by other investigators. 1, 13 
RESULTS

Patients
Thirteen patients who fulfilled the criteria for diagnosis of ADEM were identified. Patients ranged in age from 5 to 17 years; there were 5 girls and 8 boys. Table 1 summarizes the clinical features and MRI and CSF findings of these patients.
Clinical Presentation
Six of 13 children had rapid progression of symptoms that required prolonged care in the ICU. Two children presented with an acute high cervical cord syndrome and with respiratory failure that developed during the few hours after admission. Three others presented with an aseptic meningitis-like picture with rapid progression to quadriparesis and coma. One child had multiple cranial neuropathies with prominent ptosis and ophthalmoplegia mimicking a myasthenic syndrome with progression over 3 to 4 days to diffuse motor weakness. The remaining 7 patients evolved subacutely over 5 to 10 days with overlapping combinations of fever, ataxia, hemiparesis or paraparesis, and mental status changes. These patients showed little change in neurologic status after hospitalization.
Patient 4 was in the fourth week of a hepatitis A infection when she suddenly developed neurologic deficits. 14 Two children had inconclusive results to testing for Lyme disease and received a 3-week course of Ceftriaxone. No infectious cause could be identified in the remaining 10 children; however, 8 of 13 children had a preceding prodrome of upper respiratory tract illness or a nonspecific febrile illness 2 to 4 weeks before presentation.
MRI Changes
All of the children in our series eventually developed changes in subcortical white matter and/or deep gray matter, brainstem, cerebellum, and spinal cord. MRI lesions were classified according to the system described by Tenembaum et al. 1 One had small white-matter lesions Ͻ5 mm (group A); 6 had large white-matter lesions (group B), and 6 had additional bithalamic involvement (group C). No pa- tients had hemorrhagic encephalomyelitis (group D). MRI changes were best seen on FLAIR and T2-weighted sequences.
Six children had MRI changes consistent with ADEM on the first study performed after presentation, within 2 to 3 days of onset of neurologic symptoms. However, 7 had initial MRIs that were normal even on retrospective review. The time lag before lesions could be identified on MRI ranged from 2 days to 25 days after onset of neurologic symptoms. Five of 7 patients with initially normal MRI findings had a rapidly progressive course. Their MRI scans showed gradual evolution of lesions over the next 1 to 4 weeks (Fig 1) . Lesions continued to evolve even after clinical improvement. Patient 12, who presented with right hemiparesis and confusion, was treated empirically with corticosteroids and showed rapid resolution of symptoms. A follow-up MRI obtained 1 month later showed a large white-matter lesion in the left parietal cortex at a time when the patient was asymptomatic.
All 6 children who had a prolonged ICU stay had lesions in the brainstem. Two children, who presented with an acute cervical cord syndrome, had MRI lesions in the cervical cord with subsequent lesions in the cervicomedullary junction and parietal subcortical white matter (patient 10) and brainstem (patient 5). The remaining 4 had extensive bilateral lesions in the basal ganglia and thalami in addition to the brainstem and subcortical white matter. Table 1 summarizes the results of CSF studies, which showed pleocytosis and/or elevated protein in 7 of 13 patients at onset. CSF oligoclonal bands were studied in 12 patients and were negative in all cases. Eight children had electroencephalograms available for review: two were normal; the remaining 6 showed slowing of background activity and focal sharp wave activity.
Other Studies
Treatment
As shown in Table 2 , 11 of 13 children were treated with high-dose methylprednisolone (20 -30 mg/kg per day for 5 days followed by a 2-week taper). One child improved spontaneously with no specific therapy. One child (patient 1), whose presentation was ptosis, ophthalmoplegia, and facial weakness and whose initial MRI was normal, received initial therapy with IVIG (0.4 mg/kg per day for 5 days) for presumed Miller-Fisher syndrome. He also underwent electromyogram and nerve conduction studies because of his striking cranial nerve involvement; these were unremarkable. He subsequently received methylprednisolone without significant improvement. Seven children improved while receiving corticosteroid therapy.
All 6 patients who had a rapidly progressive course were given IVIG (a total of 4 g/kg over 5 days) in addition to corticosteroids. When they failed to show significant improvement, all 6 had plasmapheresis. This group included the 2 children who presented with high cervical cord symptoms and respiratory failure (patients 5 and 10).
Hospital Course
Four children deteriorated rapidly during the first week of hospitalization. Nine had maximal deficits at the time of hospitalization. Six children required mechanical ventilation for respiratory failure, and 4 needed tracheotomies for prolonged ventilatory requirements. These 6 children were the same ones who received plasmapheresis. Duration of hospital stay ranged from 3 to 75 days (median: 30 days).
Outcome
Seven of 13 children had complete recovery with an EDSS score of 0 to 1. All those who received plasmapheresis had a prolonged ICU stay and were Fig 1. A, Initial axial T2-weighted cerebral MRI (patient 11) obtained when the patient was obtunded demonstrates no abnormalities. B, Follow-up axial T2-weighted cerebral MRI 9 days later demonstrates patchy demyelinating hyperintense lesions in subcortical white matter, basal ganglia, and thalami. discharged to inpatient rehabilitation facilities. At the time of discharge, all had improved. Duration of follow-up ranged from 1.5 to 5 years (median: 2 years). Five of the 6 children who received plasmapheresis had substantial recovery with decannulation of tracheotomies. At the time of last follow-up, 1 had excellent recovery with no deficits; 3 children had a residual spastic paraparesis (EDSS 5-6.5), and 1 child had persistent ophthalmoplegia and cranial nerve dysfunction (EDSS 3.5). One child was lost to follow-up as her family moved out of state.
One child (patient 4) developed new symptoms and new lesions on MRI within 6 months of the initial presentation. She initially presented with flaccid diplegia, with rapid progression to coma, quadriplegia, and bladder dysfunction. Her admission MRI showed normal spinal cord and brain; follow-up studies showed progressive areas of enhancing high signal in the periaqueductal area, basal ganglia, centrum semiovale, and internal capsule. She was given intravenous methylprednisolone and IVIG, followed by 5 courses of plasmapheresis with gradual improvement. She was discharged after a 6-week hospitalization to a rehabilitation facility. Three months after the initial episode of ADEM, she developed alteration in mental status and retrobulbar optic neuritis. MRI showed multiple gadoliniumenhancing lesions in frontal, temporal, and parietal white matter. She received another course of methylprednisolone with clinical improvement and resolution of MRI abnormalities. She has not developed any additional episodes of demyelination in the subsequent 5 years.
DISCUSSION
Thirteen cases of ADEM were identified over a 5-year period from a single children's hospital. In the past, ADEM has been associated with vaccinations or viral exanthema. No clear-cut preceding infectious cause was identified in the majority of instances, similar to what has been reported in other pediatric series. 1 One child had a preceding infection with hepatitis A. 14 Early studies of ADEM reported mortality rates up to 20% with a high incidence of neurologic sequelae in survivors. Recent pediatric reports 1, 4, 13, 15 have suggested a more favorable prognosis attributed to treatment with corticosteroids. In our present series, 6 of 13 patients had a prolonged ICU course and multiple deficits at the time of discharge and followup. Therefore, there is a subset of children who have a more aggressive course. In our experience, children who had extensive lesions in the brainstem or cervical cord had more deficits compared with those whose lesions were mainly in the cerebellum or subcortical white matter.
MRI is regarded as the imaging modality of choice in diagnosing ADEM. 5, 6, 16 However, a significant proportion (7 of 13) of our patients had normal MRI scans at a time of maximal neurologic deficits. Some did not exhibit significant imaging changes until a few weeks into the illness, leading to potential delay in the diagnosis and treatment, and 1 child (patient 13) showed progression of lesions after clinical improvement. Therefore, a significant lag between clinical course and imaging changes occurs. Honkaniemi et al 17 described delayed MRI imaging changes in ADEM in 4 adult patients as did a case report by Murray et al, 18 but this has not been reported in children. In our series, 5 of 7 patients with a delay in diagnostic imaging changes had rapid progression of symptoms. Because these patients eventually had a high number of lesions in the deep gray nuclei and brainstem, it is possible that lesions in these areas take a longer time to evolve and become visible with currently used, standard resolution MRI. It is noteworthy that all 4 patients in the adult series 17 also had rapid deterioration followed by gradual improvement. It is possible that in patients with a more rapidly progressive course, lesions are not apparent at the time of presentation or shortly thereafter, as compared with patients with a more subacute presentation. This again points to the heterogeneous nature of ADEM and its varied clinical presentation. One could also speculate that the pathogenesis of these cases with delayed MRI changes may be dif- ferent from those of "typical" ADEM. Our data suggest that the absence of white-matter changes on MRI up to 3 weeks into the illness does not exclude the diagnosis of ADEM; treatment should not be delayed when clinical suspicion is high. The pathogenesis of ADEM is thought to be disseminated multifocal inflammation and patchy demyelination associated with autoimmune mechanisms in the CNS. ADEM occurs after infection by a virus or may be associated with immunization against rabies, diphtheria-pertussis-tetanus, or other pathogens. Antibodies to these pathogens may exhibit cross-immunoreactivity with myelin basic protein in the white matter. The pathologic findings in ADEM of demyelination and perivenous invasion of lymphocytes and monocytes are similar to those in experimental autoimmune encephalomyelitis, an accepted experimental model for acute demyelination. 19 Although ADEM is typically described as a monophasic illness that lasts from 2 to 4 weeks, relapses have been reported, [1] [2] [3] 20, 21 raising the question of whether these cases represent instances of multiple sclerosis (MS). One of our patients (patient 5) had relapsing disease. Other investigators 1, 20 have suggested the term biphasic disseminated encephalomyelitis (BDEM) or multiphasic disseminated encephalomyelitis (MDEM) for these patients. The diagnosis of BDEM or MDEM, in contrast to MS, is supported by the following: florid polysymptomatic presentation, lack of oligoclonal bands in the CSF, predominance of MRI lesions in the subcortical region with relative sparing of the periventricular areas but with possible involvement of the deep gray matter, complete or partial resolution of MRI lesions during convalescence, and recurrence within 6 months of a previous episode. 1, 20 Our patient with BDEM (patient 5) fulfilled these criteria. According to current diagnostic criteria, presence of new lesions on MRI repeated 3 months after the attack is predictive of MS. 22, 23 Most children with MS show new lesions on MRI repeated within 2 years even when they remain asymptomatic. None of our children did.
Because of the suggested immune-mediated pathogenesis, immune-modulating agents, especially corticosteroids, have been used in the treatment of ADEM. Despite the lack of controlled studies to prove their efficacy, there is strong anecdotal evidence of their benefit. Recent pediatric case series have reported wide usage of corticosteroids; 74% of 31 children in a recent Australian series 4 and 87% of 35 children in a British series 20 had good response to therapy. A large pediatric series of 84 patients from Argentina 1 also reported good recovery and resolution of MRI lesions with the use of high-dose corticosteroids in 80 of 84 children. The use of IVIG is less widespread but has been described in a few case reports and small series 3,9,10,24,25 in children, usually for patients who did not respond to corticosteroids.
Plasmapheresis has a definite role in the treatment of neurologic conditions that are presumed to be immunologically mediated, such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, polyneuropathies associated with monoclonal gammopathies, and myasthenia gravis. 26 It has been suggested that plasmapheresis also may have a role in treating patients with acute demyelination, including MS and ADEM. 26, 27 However, there have been few reports of its use in ADEM. Two adult case series reported 2 and 4 adults, respectively, 10,28 who had rapidly progressive ADEM and improved after plasmapheresis. A recent study from the Mayo Clinic 29 reviewed 59 consecutive patients who were treated with plasma exchange for acute, severe attacks of CNS demyelination. Ten of these had ADEM; 4 of 10 had a moderate to marked improvement after plasmapheresis.
To our knowledge, only 3 children who underwent plasmapheresis to treat ADEM after failure to respond to corticosteroids and/or IVIG were reported previously. 27, 30, 31 All 3 reports documented improvement after plasmapheresis.
A drawback of our series is its retrospective nature and heterogeneous characteristics of neurologic deficits. In our series, methylprednisolone was used as initial therapy in almost all instances (11 of 13), followed by IVIG when there was progression or failure of significant neurologic deficits to improve. Six of our patients then received plasmapheresis when they failed to show improvement. At the time of completion of plasmapheresis, all had begun to show improvement. Whether improvement in clinical status can be attributed to plasmapheresis, the previous use of immune-modulating therapies, or the natural course of the disease itself cannot be determined. There were no complications from the use of plasmapheresis in our patients. Potential complications reported by others 29, 32 include central line sepsis, hypotension, anemia, electrolyte abnormalities, and heparin-induced thrombocytopenia.
Our treatment has evolved to include initial treatment with corticosteroids for 5 days followed by observation for 3 to 5 days, then IVIG for 5 days followed by observation for 3 to 5 days. If there has been no significant improvement or there is worsening of neurologic function, then plasmapheresis is performed for 5 courses every other day.
Plasmapheresis should be considered as a treatment option for patients with ADEM, especially when the course is aggressive or severe disease has not responded to corticosteroids and IVIG. It is unclear whether the use of plasmapheresis early in the course of the disease would alter the prognosis. A multicenter prospective study to address the outcome of the use of different therapeutic modalities in the treatment of ADEM is warranted.
